



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of European Medicines

Agency (EMA), Scientific Committee members and experts

Public declaration of interests

I, **Nicholas Moore**

Organisation/Company: University of Victor Segalen

Country: France

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment with a Company

No Interest Declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
03/2011-(current)	Celgene	Revlimid	Advice on setting up RMP - second primary cancers
10/2009-09/2010	Axcan (Aptalis)	Pylera	HP - preparation of RMP post marketing in Europe
06/2000-(current)	Novartis	Voltaren Dolo	Assessment of various toxicities / Response to regulatory questions
02/2002-09/2007	Helsinn Healthcare	Nimesulide	assessment of Hepatic toxicity
06/1999-07/2010	Boots & reckitt bencizer	ibuprofen low-dose	general safety issues,
09/2011-(current)	Glaxo Smithkline	Pharmacovigilance systems and	pharmacoepidemiology training
08/2010-(current)	Cephalon	Effentora	Pharmacokinetic assessment
03/2007-(current)	Ethicon	SAGB : gastric medical device	Independent DSMB in clinical trial
08/2011-(current)	Genopharm	Davoban	cardiovascular risk assessment
03/1998-06/2010	Lundbeck	Sertindole	Drug safety assessment - DSMB
04/2008-08/2011	Warner Chilcott	Intrinsa	Female sexual deficit disorder: DSMB
05/2012-10/2012	SAnoti	In-house training on methods in pharmacoepidemiology: 2 times 3 day training	
06/2010-(current)	Sanofi	Participation in inhouse expert review boards for issues in	

pharmacoeconomics concerning various products or areas of interest (eg, data sources in asia or use of reimbursement databases in Europe)

2.3 Strategic Advisory Role

No Interest Declared

2.4 Current Financial Interests

No Interest Declared

2.5 Patent

No Interest Declared

2.6 Principal Investigator

Period	Company	Products	Therapeutic Indication
02/2002-09/2005	Merck - Pfizer	Vioxx - celebrex	Drug utilisation study: CADEUS
03/2005-12/2008	UCB	Keppra	Effectiveness study (EULEV)
06/2003-10/2007	Aventis	Ketek	Comparative effectiveness studies ABSINTHE & THEATRE
10/2008-12/2012	Helsinn	Nimesulide	SALT study of liver transplantation
03/2009-07/2011	Genevrier	/	Cost of psoriasis in real life
02/2008-07/2011	AFRETH (thermal stations)	None	Effect of thermal (spa) stay on metabolic syndrome (PRISME study)
11/2006-07/2011	Roche & French govt	Avastin	Effectiveness in real-life: the ETNA study
02/2006-(current)	Pierre Fabre	Omacor	Outcomes after myocardial infarction the EOLE Study
06/2012-(current)	Novartis	Lucentis	Diabetic and venous thrombosis retinopathies
03/2005-12/2010	J&J	Velcade	Multiple myeloma
02/2005-03/2007	Arkopharma	Eucalyptus cigarette	smoking cessation
06/2005-06/2006	GSK	ropinirole	restless legs syndrome
10/2009-(current)	Nycomed/takeda	Instanyl	Breakthrough pain
07/2011-08/2011	Novartis	Exforge	Drug utilisation study
11/2010-06/2011	Sanofi	Lantus	Risk of cancer?
08/2011-08/2012	Sanofi	Apidra	Drug utilisation study
04/2012-(current)	Aptalis	Pylera	Drug utilisation study

2.7 Investigator

No Interest Declared

2.8 Grant / Funding to Institution

Company	Subject Matter
Abbott	Training tax to university

Arkopharma	Training tax to university
Astrazeneca	Training tax to university
Bayer	Training tax to university
Biopharma	Training tax to university
BMS	Training tax to university
Boehringer-Ingelheim	Training tax to university
Daichii-Sankyo	Training tax to university
Génévrier	Training tax to university
Grunenthal	Training tax to university
GSK	Training tax to university
Horus Pharma	Training tax to university
Innothera	Training tax to university
IPSEN	Training tax to university
Janssen-Cilag	Training tax to university
Lilly	Training tax to university
Lundbeck	Training tax to university
Meda	Training tax to university
Medtronic	Training tax to university
Merck & Co	Training tax to university
Merck-Serono	Training tax to university
Norgine	Training tax to university
Novo-Nordisk	Training tax to university
Pfizer	Training tax to university
Pierre Fabre	Training tax to university
Proctor & Gamble	Training tax to university
Roche	Training tax to university
Sanofi	Training tax to university
Schering-Plough	Training tax to university
Stallergènes	Training tax to university
Takeda	Training tax to university
Teva	Training tax to university
Vivalis	Training tax to university
Helsinn	Donation to university Foundation
Novartis family Health	Donation to University Foundation

2.9 Family Member Interest

No Interest Declared

Other Interests or Facts

I know many persons who work, have worked or will work in the pharmaceutical industry, and who will sometimes buy me a drink (and vice-versa) and discuss concerns.

I am coordinator of a Clinical Research Centre in a University Hospital, with about 200 ongoing studies half with industry, of which I am not investigator

I was coordinator of Clinical Research for the University hospitals in Bordeaux with over 1000 industry-sponsored clinical trials ongoing, all of which reimburse the hospital and the investigators (not me) for costs related to the research.

SECTION 3: CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:


- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the EMA website.

Full Name: Nicholas Moore

Date: 2013-05-09

 INSERM CIC 0005 Pharmaco-Epidémiologie
Pr N. MOORE - Service de Pharmacologie
Université de Bordeaux - CHU de Bordeaux
Bât. Le Tondu - Case 41
146 rue Léo Saignat
33076 Bordeaux cedex

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template